Wall Street analysts forecast that Zoetis (ZTS) will report quarterly earnings of $1.40 per share in its upcoming release, pointing to no change from the year-ago quarter. It is anticipated that revenues will amount to $2.37 billion, exhibiting an increase of 2.1% compared to the year-ago quarter.Over the last 30 days, there has been an upward revision of 0.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of thei ...

Well, as you highlighted, HIMS cratering while Novo shares pop. The pharma giant filing a lawsuit this morning against the tellahalth company, asking the court to permanently ban HIMS from selling all compounded versions of its drugs, citing patent infringement. The FDA, which referred HIMS to the DOJ on Friday, also threatened legal action.Now, in response over the weekend, HIMS said they would pull their GLP-1 oral medicine that they announced only a few days prior. Novo in the complaint saying, "Other ph ...

Vancouver, British Columbia, February 9th, 2026, FinanceWireOptimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a Health Canada-licensed manufacturer of pharmaceutical psychoactive medication products, today reported that it has completed its first export of MD-MA capsules to Australia in 2026 under the Authorised Prescriber Scheme.The export included 1,000 of Optimi’s MD-MA capsules in a standardised 60 mg dosage form, supplied for use in authorised clinical programs for th ...

For years, investors have discounted Merck ( MRK ) due to the coming loss of exclusivity [LOE] for Keytruda in 2028. While headlines from last week's earnings report focused on softer-than-expected guidance, investors may have overlooked a bullishBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employme ...

Economic Data Releases - The upcoming week will feature significant US economic data releases, including the January employment report and the January CPI report, which are typically not released in the same week [1] - December retail sales and the Q4 employment cost index will also be released, alongside global inflation updates from China and several European economies [1] Employment Report Expectations - DB economists project a rise in headline and private payrolls by 75k, with the unemployment rate expected to remain at 4.4% [2] - Average hourly earnings are anticipated to increase by 0.3%, with hours worked remaining unchanged at 34.2, leading to a year-over-year growth rate of payroll-based nominal compensation rising to 4.5% from 4.3% [2] Inflation Report Expectations - The headline CPI is expected to increase by 0.26%, influenced by a projected 2.4% drop in motor fuel prices, while core CPI is anticipated to rise by 0.35% [4] - This would result in a year-over-year headline CPI slowing to 2.46% from 2.68%, and core CPI to approximately 2.55% [4] Corporate Earnings - Corporate earnings reports are ongoing, with six of the Magnificent Seven having reported, which may reduce volatility until Nvidia's report on February 25th [1] - The week will also see earnings from major tech companies and consumer firms, including Cisco, Coca-Cola, and McDonald's [8] Fed Communications - Fed officials will be actively communicating throughout the week, discussing regulatory topics and the balance sheet outlook, particularly in light of the nomination of Kevin Warsh for Fed Chair [6] - Discussions will include perspectives on the labor market and inflation, with various Fed governors scheduled to speak [6][20] Global Economic Indicators - In Europe, key indicators include the UK's Q4 GDP and CPI reports from Denmark, Norway, and Switzerland [7] - In Asia, China's January inflation report is due, with forecasts indicating a slowdown in CPI inflation to 0.4% year-over-year [8]

For years, investors have discounted Merck ( MRK ) due to the coming loss of exclusivity [LOE] for Keytruda in 2028. While headlines from last week's earnings report focused on softer-than-expected guidance, investors may have overlooked a bullishBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employme ...

Let's begin with Novo Nordisk suing hims and hers, accusing the telehealth firm of infringing its U.S. patent on key ingredient in its epic. And we go by. Let's get the latest.The same for he's the senior pharmaceutical analyst at Bloomberg Intelligence. Sam, we were just talking on Friday and you were telling us there is a danger to this. This isn't good.It sounds like hims and hers has finally listened to some of the criticism and threats coming from regulators. Yeah, well, Daddy, the point here is not ab ...

Let's begin with Novo Nordisk suing hims and hers, accusing the telehealth firm of infringing its U.S. patent on key ingredient in its epic. And we go by. Let's get the latest.The same for he's the senior pharmaceutical analyst at Bloomberg Intelligence. Sam, we were just talking on Friday and you were telling us there is a danger to this. This isn't good.It sounds like hims and hers has finally listened to some of the criticism and threats coming from regulators. Yeah, well, Daddy, the point here is not ab ...

Biofrontera Inc. (BFRI), Monday announced positive and statistically significant top-line results from its Phase 3 clinical trial, evaluating Ameluz PDT with the red-light LEDplatform for the treatment of mild to moderate actinic keratoses on the extremities, neck, and trunk.Despite these positive findings, Biofrontera's stock is moving down 8.66 percent, to $0.75 on the Nasdaq. The stock opened at $0.7 and has traded as far as $0.96 in today's session.The multicenter, randomized, double-blind, vehicle-con ...

Novo Nordisk A/S (NYSE:NVO) on Monday said it has filed a lawsuit against telehealth company Hims & Hers Inc. (NYSE:HIMS) for infringing U.S. Patent 8,129,343 with Hims’ compounded semaglutide products for the U.S. market.Novo Nordisk’s Legal Move ExplainedNovo Nordisk, in its press release, said Hims & Hers engaged in promotional campaigns that highlight its compounded semaglutide products, duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs.Hims c ...